Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220252) titled 'Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis' on Oct. 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: TG Therapeutics, Inc.

Condition: Relapsing Multiple Sclerosis

Intervention: Drug: Ublituximab Drug: Placebo Drug: Placebo

Recruitment Status: Not recruiting

Phase: Phase 2/Phase 3

Date of First Enrollment: December 1, 2025

Target Sample Size: 240

To know m...